The Independent Standard for Pharmaceutical Reimbursement Risk
A Committee-Based Rating System Calibrated to Historical HTA Outcomes Across US, EU4, UK and Japan.
What MARA Rating Provides
MARA Rating is an independent, standardized assessment of pharmaceutical market access risk.
Regulatory approval does not guarantee reimbursement.
HTA agencies and payers act as a second gate.
MARA synthesizes evidence across 10 payer-relevant domains — including comparative effectiveness, safety, cost-effectiveness, budget impact, and evidence strength — into a single, comparable rating band (A++ to C).
The objective is not to replace judgment.
It is to reduce variance, surface hidden constraints, and provide a defensible benchmark before capital is committed.
How the MARA Rating Is Determined
Structured evaluation across 10 calibrated domains
Public, verifiable evidence sources only
Committee-based judgment; no single analyst determines outcome
Minutes recorded and conflict-of-interest controls enforced
Calibrated against historical HTA outcomes
Subject to defined surveillance and rating actions
Used in High-Stakes Decision Contexts
MARA Ratings are designed to support:
Pre-deal due diligence and valuation stress-testing
Phase 2 → Phase 3 investment decisions
Pre-launch pricing and reimbursement governance
Portfolio reprioritization
Investor memoranda and capital allocation discussions
Core principle:
If this decision is challenged later, what independent reimbursement benchmark was relied upon?
Rating Products
Single-Asset MARA Rating (Internal Use License)
Full committee-based rating with drivers, rationale, benchmarking, and surveillance status.
Therapeutic Area Benchmark Pack
Side-by-side rating comparison across assets within a defined therapeutic area.
Portfolio Access (Institutional License)
Structured access to multiple ratings and rating updates across defined asset groups.
Note: Public display of a MARA Rating requires a valid Display License.
Governance & Calibration
Published methodology framework
Defined rating action categories
Committee charter and conflict-of-interest controls
Calibration against retrospective HTA outcomes
Ongoing surveillance and periodic review
Rating Committee Charter
Annual Calibration Process
Obtain an independent reimbursement risk benchmark.
Methodology Overview (2 Minutes)
This short overview explains the structured evaluation process, committee governance, and calibration principles underlying the MARA Rating.
Check out our Youtube channel here.
Contact a MARA Analyst
Have a molecule in mind—or just a market access pharma question? Send us a note to sales@mararating.com and one of our analysts will reply within one business day. All inquiries are confidential.
"*" indicates required fields
Market Access & Capital Risk Insights
Eli Lilly’s 340B Ultimatum: What Does It Mean for Market Access?
Summary Eli Lilly has given hospitals in the 340B drug discount program until Monday, June 9, 2026, to comply with
Bysanti / Milsaperidone: The evidence answered questions about a different drug.
We have just published a MARA Rating for a treatment for schizophrenia and bipolar disorder. The clinical question payers must
Retatrutide: The most effective weight-loss result seen to date. The access question has not been asked yet.
We have just published a MARA Rating for an obesity treatment that has not yet completed Phase 3 trials. The
Pfizer and Innovent Strike $10B Cancer Drug Deal: What Does It Mean for Market Access?
Summary Pfizer announced on May 29, 2026 a broad oncology alliance with China’s Innovent Biologics valued at up to $10.5
Servier’s $2.7B Bet on Muscular Dystrophy: The Market Access Risk Behind the Headline Number
Summary Servier agreed on June 1 to acquire sevasemten from Edgewise Therapeutics for up to $2.7 billion. The drug targets
Sibeprenlimab / VOYXACT: The trial measured protein in the urine. Payers need to know about kidneys.
We recently completed a MARA Rating for a treatment for a kidney disease that can progress to kidney failure over